Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2012 (2012), Article ID 456478, 13 pages
http://dx.doi.org/10.1155/2012/456478
Review Article

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets

1Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan
2Department of Neurology, National Taiwan University Hospital, Yun-lin Branch, Yun-lin 64041, Taiwan

Received 1 March 2012; Revised 5 April 2012; Accepted 6 April 2012

Academic Editor: Hansen Wang

Copyright © 2012 Li-Kai Tsai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. Lunn and C. H. Wang, “Spinal muscular atrophy,” The Lancet, vol. 371, no. 9630, pp. 2120–2133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Feldkötter, V. Schwarzer, R. Wirth, T. F. Wienker, and B. Wirth, “Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy,” American Journal of Human Genetics, vol. 70, no. 2, pp. 358–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Pearn, “Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy,” Journal of Medical Genetics, vol. 15, no. 6, pp. 409–413, 1978. View at Google Scholar · View at Scopus
  4. J. C. Kaplan, “Gene table of monogenic neuromuscular disorders (nuclear genome only),” Neuromuscular Disease, vol. 19, no. 1, pp. 77–98, 2009. View at Google Scholar
  5. S. Lefebvre, L. Bürglen, S. Reboullet et al., “Identification and characterization of a spinal muscular atrophy-determining gene,” Cell, vol. 80, no. 1, pp. 155–165, 1995. View at Google Scholar · View at Scopus
  6. B. Wirth, “An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA),” Human Mutation, vol. 15, no. 3, pp. 228–237, 2000. View at Google Scholar
  7. S. Lefebvre, P. Burlet, Q. Liu et al., “Correlation between severity and SMN protein level in spinal muscular atrophy,” Nature Genetics, vol. 16, no. 3, pp. 265–269, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. U. R. Monani, D. D. Coovert, and A. H. M. Burghes, “Animal models of spinal muscular atrophy,” Human Molecular Genetics, vol. 9, no. 16, pp. 2451–2457, 2000. View at Google Scholar · View at Scopus
  9. M. Sendtner, “Therapy development in spinal muscular atrophy,” Nature Neuroscience, vol. 13, no. 7, pp. 795–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Lorson, H. Rindt, and M. Shababi, “Spinal muscular atrophy: mechanisms and therapeutic strategies,” Human Molecular Genetics, vol. 19, no. R1, pp. R111–R118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Bosch-Marcé, C. D. Wee, T. L. Martinez et al., “Increased IGF-1 in muscle modulates the phenotype of severe SMA mice,” Human Molecular Genetics, vol. 20, no. 9, pp. 1844–1853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Shababi, J. Glascock, and C. L. Lorson, “Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy,” Human Gene Therapy, vol. 22, no. 2, pp. 135–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Simon, S. Jablonka, R. Ruiz, L. Tabares, and M. Sendtner, “Ciliary neurotrophic factor-induced sprouting preserves motor function in a mouse model of mild spinal muscular atrophy,” Human Molecular Genetics, vol. 19, no. 6, pp. 973–986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Lesbordes, C. Cifuentes-Diaz, A. Miroglio et al., “Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy,” Human Molecular Genetics, vol. 12, no. 11, pp. 1233–1239, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. F. F. Rose Jr., V. B. Mattis Jr., H. Rindt, and C. L. Lorson, “Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy,” Human Molecular Genetics, vol. 18, no. 6, pp. 997–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. S. Tsai, Y. T. Chiu, S. H. Wang, H. M. Hsieh-Li, W. C. Lian, and H. Li, “Abolishing bax-dependent apoptosis shows beneficial effects on spinal muscular atrophy model mice,” Molecular Therapy, vol. 13, no. 6, pp. 1149–1155, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. K. Tsai, M. S. Tsai, C. H. Ting, S. H. Wang, and H. Li, “Restoring Bcl-xL levels benefits a mouse model of spinal muscular atrophy,” Neurobiology of Disease, vol. 31, no. 3, pp. 361–367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. E. Oprea, S. Kröber, M. L. McWhorter et al., “Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy,” Science, vol. 320, no. 5875, pp. 524–527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Corti, M. Nizzardo, M. Nardini et al., “Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy,” Journal of Clinical Investigation, vol. 118, no. 10, pp. 3316–3330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Corti, M. Nizzardo, M. Nardini et al., “Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice,” Brain, vol. 133, no. 2, pp. 465–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Young, T. T. Le, N. thi Man, A. H. M. Burghes, and G. E. Morris, “The relationship between SMN, the spinal muscular atrophy protein, and nuclear coiled bodies in differentiated tissues and cultured cells,” Experimental Cell Research, vol. 256, no. 2, pp. 365–374, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. U. Fischer, Q. Liu, and G. Dreyfuss, “The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis,” Cell, vol. 90, no. 6, pp. 1023–1029, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Pellizzoni, J. Yong, and G. Dreyfuss, “Essential role for the SMN complex in the specificity of snRNP assembly,” Science, vol. 298, no. 5599, pp. 1775–1779, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Gabanella, M. E. R. Butchbach, L. Saieva, C. Carissimi, A. H. M. Burghes, and L. Pellizzoni, “Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs,” PLoS ONE, vol. 2, no. 9, article e921, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kariya, G. H. Park, Y. Maeno-Hikichi et al., “Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy,” Human Molecular Genetics, vol. 17, no. 16, pp. 2552–2569, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Jablonka, M. Beck, B. D. Lechner, C. Mayer, and M. Sendtner, “Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy,” Journal of Cell Biology, vol. 179, no. 1, pp. 139–149, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Fan and L. R. Simard, “Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development,” Human Molecular Genetics, vol. 11, no. 14, pp. 1605–1614, 2002. View at Google Scholar · View at Scopus
  28. A. H. M. Burghes and C. E. Beattie, “Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?” Nature Reviews Neuroscience, vol. 10, no. 8, pp. 597–609, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. L. Zhang, F. Pan, D. Hong, S. M. Shenoy, R. H. Singer, and G. J. Bassell, “Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization,” Journal of Neuroscience, vol. 23, no. 16, pp. 6627–6637, 2003. View at Google Scholar · View at Scopus
  30. W. Rossoll, S. Jablonka, C. Andreassi et al., “Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons,” Journal of Cell Biology, vol. 163, no. 4, pp. 801–812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. M. Hsieh-Li, J. G. Chang, Y. J. Jong et al., “A mouse model for spinal muscular atrophy,” Nature Genetics, vol. 24, no. 1, pp. 66–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. L. M. Murray, S. Lee, D. Bäumer, S. H. Parson, K. Talbot, and T. H. Gillingwater, “Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy,” Human Molecular Genetics, vol. 19, no. 3, pp. 420–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Bäumer, S. Lee, G. Nicholson et al., “Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy,” PLoS Genetics, vol. 5, no. 12, Article ID e1000773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Desjardins and S. Ledoux, “The role of apoptosis in neurodegenerative diseases,” Metabolic Brain Disease, vol. 13, no. 2, pp. 79–96, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Rudnik-Schöneborn, R. Heller, C. Berg et al., “Congenital heart disease is a feature of severe infantile spinal muscular atrophy,” Journal of Medical Genetics, vol. 45, no. 10, pp. 635–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Shababi, J. Habibi, H. T. Yang, S. M. Vale, W. A. Sewell, and C. L. Lorson, “Cardiac defects contribute to the pathology of spinal muscular atrophy models,” Human Molecular Genetics, vol. 19, no. 20, pp. 4059–4071, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. C. R. Heier, R. Satta, C. Lutz, and C. J. Didonato, “Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice,” Human Molecular Genetics, vol. 19, no. 20, Article ID ddq330, pp. 3906–3918, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Shababi, J. Habibi, L. Ma, J. J. Glascock, J. R. Sowers, and C. L. Lorson, “Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 5, pp. 1074–1082, 2012. View at Publisher · View at Google Scholar
  39. Y. Hua, K. Sahashi, F. Rigo et al., “Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model,” Nature, vol. 478, no. 7367, pp. 123–126, 2011. View at Google Scholar
  40. D. D. Coovert, T. T. Le, P. E. McAndrew et al., “The survival motor neuron protein in spinal muscular atrophy,” Human Molecular Genetics, vol. 6, no. 8, pp. 1205–1214, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. J. G. Chang, H. M. Hsieh-Li, Y. J. Jong, N. M. Wang, C. H. Tsai, and H. Li, “Treatment of spinal muscular atrophy by sodium butyrate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9808–9813, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Mercuri, E. Bertini, S. Messina et al., “Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy,” Neurology, vol. 68, no. 1, pp. 51–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. L. K. Tsai, M. S. Tsai, C. H. Ting, and H. Li, “Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice,” Journal of Molecular Medicine, vol. 86, no. 11, pp. 1243–1254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Avila, B. G. Burnett, A. A. Taye et al., “Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 659–671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Riessland, B. Ackermann, A. Förster et al., “SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy,” Human Molecular Genetics, vol. 19, no. 8, pp. 1492–1506, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Garbes, M. Riessland, I. Hölker et al., “LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate,” Human Molecular Genetics, vol. 18, no. 19, pp. 3645–3658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. T. H. Chen, J. G. Chang, Y. H. Yang et al., “Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy,” Neurology, vol. 75, no. 24, pp. 2190–2197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. L. Zhang, C. L. Lorson, E. J. Androphy, and J. Zhou, “An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA,” Gene Therapy, vol. 8, no. 20, pp. 1532–1538, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Andreassi, J. Jarecki, J. Zhou et al., “Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients,” Human Molecular Genetics, vol. 10, no. 24, pp. 2841–2849, 2001. View at Google Scholar · View at Scopus
  50. M. R. Lunn, D. E. Root, A. M. Martino et al., “Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism,” Chemistry and Biology, vol. 11, no. 11, pp. 1489–1493, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Y. Kwon, W. W. Motley, K. H. Fischbeck, and B. G. Burnett, “Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice,” Human Molecular Genetics, vol. 20, no. 18, pp. 3667–3677, 2011. View at Google Scholar
  52. E. C. Wolstencroft, V. B. Mattis Jr., A. A. Bajer, P. J. Young, and C. L. Lorson, “A non-sequence-apecific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels,” Human Molecular Genetics, vol. 14, no. 9, pp. 1199–1210, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. V. B. Mattis Jr., A. D. Ebert, M. Y. Fosso, C. W. Chang, and C. L. Lorson, “Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model,” Human Molecular Genetics, vol. 18, no. 20, pp. 3906–3913, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. C. R. Heier and C. J. DiDonato, “Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo,” Human Molecular Genetics, vol. 18, no. 7, pp. 1310–1322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. W. M. Bosboom, A. F. Vrancken, L. H. van den Berg, J. H. Wokke, and S. T. Iannaccone, “Drug treatment for spinal muscular atrophy type I,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD006281, 2009. View at Google Scholar · View at Scopus
  56. W. M. Bosboom, A. F. Vrancken, L. H. van den Berg, J. H. Wokke, and S. T. Iannaccone, “Drug treatment for spinal muscular atrophy types II and III,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD006282, 2009. View at Google Scholar · View at Scopus
  57. C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar, and P. S. Klein, “Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen,” Journal of Biological Chemistry, vol. 276, no. 39, pp. 36734–36741, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Brichta, Y. Hofmann, E. Hahnen et al., “Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy,” Human Molecular Genetics, vol. 12, no. 19, pp. 2481–2489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C. J. Sumner, T. N. Huynh, J. A. Markowitz et al., “Valproic acid increases smn levels in spinal muscular atrophy patient cells,” Annals of Neurology, vol. 54, no. 5, pp. 647–654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Wong and A. M. Cuervo, “Autophagy gone awry in neurodegenerative diseases,” Nature Neuroscience, vol. 13, no. 7, pp. 805–811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Xiong, M. Jia, C. Chen et al., “Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y,” Neuroscience, vol. 199, pp. 292–302, 2011. View at Google Scholar
  62. G. Chen, W. Z. Zeng, P. X. Yuan et al., “The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS,” Journal of Neurochemistry, vol. 72, no. 2, pp. 879–882, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Einat, P. Yuan, T. D. Gould et al., “The role of the extracellular signal-regulated kinase signaling pathway in mood modulation,” Journal of Neuroscience, vol. 23, no. 19, pp. 7311–7316, 2003. View at Google Scholar · View at Scopus
  64. L. K. Tsai, M. S. Tsai, T. B. Lin, W. L. Hwu, and H. Li, “Establishing a standardized therapeutic testing protocol for spinal muscular atrophy,” Neurobiology of Disease, vol. 24, no. 2, pp. 286–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. C. Weihl, A. M. Connolly, and A. Pestronk, “Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy,” Neurology, vol. 67, no. 3, pp. 500–501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. L. K. Tsai, C. C. Yang, W. L. Hwu, and H. Li, “Valproic acid treatment in six patients with spinal muscular atrophy,” European Journal of Neurology, vol. 14, no. 12, pp. e8–e9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. K. J. Swoboda, C. B. Scott, S. P. Reyna et al., “Phase II open label study of valproic acid in spinal muscular atrophy,” PLoS ONE, vol. 4, no. 5, Article ID e5268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. K. J. Swoboda, C. B. Scott, T. O. Crawford et al., “SMA carni-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy,” PLoS ONE, vol. 5, no. 8, Article ID e12140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. J. T. Kissel, C. B. Scott, S. P. Reyna et al., “SMA carni-VAL trial part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy,” PLoS ONE, vol. 6, no. 7, Article ID e21296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Also-Rallo, L. Alías, R. Martínez-Hernández et al., “Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability,” European Journal of Human Genetics, vol. 19, pp. 1059–1065, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Nlend, K. Meyer, and D. Schümperli, “Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy,” RNA Biology, vol. 7, no. 4, pp. 430–440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Marquis, K. Meyer, L. Angehrn, S. S. Kämpfer, B. Rothen-Rutishauser, and D. Schümperli, “Spinal muscular atrophy: SMN2 Pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence,” Molecular Therapy, vol. 15, no. 8, pp. 1479–1486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. T. D. Baughan, A. Dickson, E. Y. Osman, and C. L. Lorson, “Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy,” Human Molecular Genetics, vol. 18, no. 9, pp. 1600–1611, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. P. N. Proensky, C. Mitrpant, V. L. McGovern et al., “A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse,” Human Molecular Genetics, vol. 21, no. 7, pp. 1625–1638, 2011. View at Publisher · View at Google Scholar
  75. M. A. Passini, J. Bu, E. M. Roskelley et al., “CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1253–1264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. K. D. Foust, E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan, and B. K. Kaspar, “Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes,” Nature Biotechnology, vol. 27, no. 1, pp. 59–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. K. D. Foust, X. Wang, V. L. McGovern et al., “Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN,” Nature Biotechnology, vol. 28, no. 3, pp. 271–274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. M. A. Passini and S. H. Cheng, “Prospects for the gene therapy of spinal muscular atrophy,” Trends in Molecular Medicine, vol. 17, no. 5, pp. 259–265, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. D. van der Marel, B. J. Anderson, M. A. L. Pluim, T. H. R. de Jong, A. Gonzalez, and D. Tibboel, “Acetaminophen in cerebrospinal fluid in children,” European Journal of Clinical Pharmacology, vol. 59, no. 4, pp. 297–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Vardatsikos, A. Sahu, and A. K. Srivastava, “The insulin-like growth factor family: molecular mechanisms, redox regulation, and clinical implications,” Antioxidants and Redox Signaling, vol. 11, no. 5, pp. 1165–1190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Humbert, E. A. Bryson, F. P. Cordelières et al., “The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt,” Developmental Cell, vol. 2, no. 6, pp. 831–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. P. J. S. Vig, S. H. Subramony, D. R. D'Souza, J. Wei, and M. E. Lopez, “Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice,” Brain Research Bulletin, vol. 69, no. 5, pp. 573–579, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. P. H. Özdinler and J. D. Macklis, “IGF-I specifically enhances axon outgrowth of corticospinal motor neurons,” Nature Neuroscience, vol. 9, no. 11, pp. 1371–1381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Powell-Braxton, P. Hollingshead, C. Warburton et al., “IGF-I is required for normal embryonic growth in mice,” Genes and Development, vol. 7, no. 12, pp. 2609–2617, 1993. View at Google Scholar · View at Scopus
  85. H. M. Domené, V. Hwa, J. Argente et al., “Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences,” Hormone Research, vol. 72, no. 3, pp. 129–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. B. K. Kaspar, J. Lladó, N. Sherkat, J. D. Rothstein, and F. H. Gage, “Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model,” Science, vol. 301, no. 5634, pp. 839–842, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. I. Palazzolo, C. Stack, L. Kong et al., “Overexpression of IGF-1 in Muscle Attenuates Disease in a Mouse Model of Spinal and Bulbar Muscular Atrophy,” Neuron, vol. 63, no. 3, pp. 316–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. L. K. Tsai, Y. C. Chen, W. C. Cheng et al., “IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice,” Neurobiology of Disease, vol. 45, no. 1, pp. 272–279, 2012. View at Google Scholar
  89. Y. J. Son and W. J. Thompson, “Nerve sprouting in muscle is induced and guided by processes extended by Schwann cells,” Neuron, vol. 14, no. 1, pp. 133–141, 1995. View at Google Scholar · View at Scopus
  90. S. Pun, A. F. Santos, S. Saxena, L. Xu, and P. Caroni, “Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF,” Nature Neuroscience, vol. 9, no. 3, pp. 408–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Sendtner, H. Schmalbruch, K. A. Stockli, P. Carroll, G. W. Kreutzberg, and H. Thoenen, “Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy,” Nature, vol. 358, no. 6386, pp. 502–504, 1992. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Sagot, T. Rosse, R. Vejsada, D. Perrelet, and A. C. Kato, “Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease,” Journal of Neuroscience, vol. 18, no. 3, pp. 1132–1141, 1998. View at Google Scholar · View at Scopus
  93. ALS CNTF Treatment Study (ACTS) Group, “A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis,” Neurology, vol. 46, no. 5, pp. 1244–1249, 1996. View at Google Scholar · View at Scopus
  94. S. Davis, T. H. Aldrich, N. Stahl et al., “LIFRβ and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor,” Science, vol. 260, no. 5115, pp. 1805–1808, 1993. View at Google Scholar · View at Scopus
  95. D. Pennica, W. I. Wood, and K. R. Chien, “Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp130 dependent pathways,” Cytokine and Growth Factor Reviews, vol. 7, no. 1, pp. 81–91, 1996. View at Publisher · View at Google Scholar · View at Scopus
  96. D. Pennica, V. Arce, T. A. Swanson et al., “Cardiotrophin-1, a cytokine present in embryonic muscle, supports long- term survival of spinal motoneurons,” Neuron, vol. 17, no. 1, pp. 63–74, 1996. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Bordet, H. Schmalbruch, B. Pettmann et al., “Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy,” Journal of Clinical Investigation, vol. 104, no. 8, pp. 1077–1085, 1999. View at Google Scholar · View at Scopus
  98. T. Bordet, J. C. Lesbordes, S. Rouhani et al., “Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice,” Human Molecular Genetics, vol. 10, no. 18, pp. 1925–1933, 2001. View at Google Scholar · View at Scopus
  99. D. E. Merry and S. J. Korsmeyer, “Bcl-2 gene family in the nervous system,” Annual Review of Neuroscience, vol. 20, pp. 245–267, 1997. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Soler-Botija, I. Ferrer, I. Gich, M. Baiget, and E. F. Tizzano, “Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord,” Brain, vol. 125, no. 7, pp. 1624–1634, 2002. View at Google Scholar · View at Scopus
  101. M. E. Garrity-Moses, Q. Teng, J. Liu, D. Tanase, and N. M. Boulis, “Neuroprotective adeno-associated virus Bcl-xL gene transfer in models of motor neuron disease,” Muscle and Nerve, vol. 32, no. 6, pp. 734–744, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Garcera, S. Mincheva, M. Gou-Fabregas et al., “A new model to study spinal muscular atrophy: neurite degeneration and cell death is counteracted by BCL-XL Overexpression in motoneurons,” Neurobiology of Disease, vol. 42, no. 3, pp. 415–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. G. Bensimon, L. Lacomblez, and V. Meininger, “A controlled trial of riluzole in amyotrophic lateral sclerosis,” The New England Journal of Medicine, vol. 330, no. 9, pp. 585–591, 1994. View at Publisher · View at Google Scholar · View at Scopus
  104. B. C. Cheah, S. Vucic, A. V. Krishnan, and M. C. Kiernan, “Riluzole, neuroprotection and amyotrophic lateral sclerosis,” Current Medicinal Chemistry, vol. 17, no. 18, pp. 1942–1959, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Haddad, C. Cifuentes-Diaz, A. Miroglio, N. Roblot, V. Joshi, and J. Melki, “Riluzole attenuates spinal muscular atrophy disease progression in a mouse model,” Muscle and Nerve, vol. 28, no. 4, pp. 432–437, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. B. S. Russman, S. T. Iannaccone, and F. J. Samaha, “A Phase 1 Trial of Riluzole in Spinal Muscular Atrophy,” Archives of Neurology, vol. 60, no. 11, pp. 1601–1603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Abbara, B. Estournet, L. Lacomblez et al., “Riluzole pharmacokinetics in young patients with spinal muscular atrophy,” British Journal of Clinical Pharmacology, vol. 71, no. 3, pp. 403–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Chadwick, “Gabapentin,” The Lancet, vol. 343, no. 8889, pp. 89–91, 1994. View at Publisher · View at Google Scholar · View at Scopus
  109. J. D. Rothstein and R. W. Kuncl, “Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity,” Journal of Neurochemistry, vol. 65, no. 2, pp. 643–651, 1995. View at Google Scholar · View at Scopus
  110. B. S. Traa, J. D. Mulholland, S. D. Kadam, M. V. Johnston, and A. M. Comi, “Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia,” Pediatric Research, vol. 64, no. 1, pp. 81–85, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. R. G. Miller, D. Moore II, L. A. Young et al., “Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis,” Neurology, vol. 47, no. 6, pp. 1383–1388, 1996. View at Google Scholar · View at Scopus
  112. R. G. Miller, D. H. Moore II, D. F. Gelinas et al., “Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis,” Neurology, vol. 56, no. 7, pp. 843–848, 2001. View at Google Scholar · View at Scopus
  113. R. G. Miller, D. H. Moore II, V. Dronsky et al., “A placebo-controlled trial of gabapentin in spinal muscular atrophy,” Journal of the Neurological Sciences, vol. 191, no. 1-2, pp. 127–131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Merlini, A. Solari, G. Vita et al., “Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study,” Journal of Child Neurology, vol. 18, no. 8, pp. 537–541, 2003. View at Google Scholar · View at Scopus
  115. J. G. Ryall, D. R. Plant, P. Gregorevic, M. N. Sillence, and G. S. Lynch, “β2-agonist administration reverses muscle wasting and improves muscle function in aged rats,” Journal of Physiology, vol. 555, no. 1, pp. 175–188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Martineau, M. A. Horan, N. J. Rothwell, and R. A. Little, “Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men,” Clinical Science, vol. 83, no. 5, pp. 615–621, 1992. View at Google Scholar · View at Scopus
  117. J. F. Signorile, K. Banovac, M. Gomez, D. Flipse, J. F. Caruso, and I. Lowensteyn, “Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-2 adrenergic agonist,” Archives of Physical Medicine and Rehabilitation, vol. 76, no. 1, pp. 55–58, 1995. View at Publisher · View at Google Scholar · View at Scopus
  118. J. T. Kissel, M. P. McDermott, J. R. Mendell et al., “Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy,” Neurology, vol. 57, no. 8, pp. 1434–1440, 2001. View at Google Scholar · View at Scopus
  119. M. Kinali, E. Mercuri, M. Main et al., “Pilot trial of albuterol in spinal muscular atrophy,” Neurology, vol. 59, no. 4, pp. 609–610, 2002. View at Google Scholar · View at Scopus
  120. M. Pane, S. Staccioli, S. Messina et al., “Daily salbutamol in young patients with SMA type II,” Neuromuscular Disorders, vol. 18, no. 7, pp. 536–540, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Angelozzi, F. Borgo, F. D. Tiziano, A. Martella, G. Neri, and C. Brahe, “Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells,” Journal of Medical Genetics, vol. 45, no. 1, pp. 29–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. F. D. Tiziano, R. Lomastro, A. M. Pinto et al., “Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design,” Journal of Medical Genetics, vol. 47, no. 12, pp. 856–858, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. A. C. McPherron, A. M. Lawler, and S. J. Lee, “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,” Nature, vol. 387, no. 6628, pp. 83–90, 1997. View at Google Scholar · View at Scopus
  124. L. Grobet, D. Pirottin, F. Farnir et al., “Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene,” Genesis, vol. 35, no. 4, pp. 227–238, 2003. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Bogdanovich, T. O. B. Krag, E. R. Barton et al., “Functional improvement of dystrophic muscle by myostatin blockade,” Nature, vol. 420, no. 6914, pp. 418–421, 2002. View at Publisher · View at Google Scholar · View at Scopus
  126. L. R. Rodino-Klapac, A. M. Haidet, J. Kota, C. Handy, B. K. Kaspar, and J. R. Mendell, “Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease,” Muscle and Nerve, vol. 39, no. 3, pp. 283–296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. T. M. Miller, S. H. Kim, K. Yamanaka et al., “Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 51, pp. 19546–19551, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. A. M. Haidet, L. Rizo, C. Handy et al., “Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4318–4322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. C. J. Sumner, C. D. Wee, L. C. Warsing et al., “Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice,” Human Molecular Genetics, vol. 18, no. 17, pp. 3145–3152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. H. Rindt, D. M. Buckley, S. M. Vale et al., “Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of spinal muscular atrophy,” Neuromuscular Disorders, vol. 22, no. 3, pp. 277–285, 2012. View at Google Scholar
  131. S. Rudnik-Schöneborn, D. Rohrig, G. Morgan, B. Wirth, and K. Zerres, “Autosomal recessive proximal spinal muscular atrophy in 101 sibs out of 48 families: clinical picture, influence of gender, and genetic implications,” American Journal of Medical Genetics, vol. 51, no. 1, pp. 70–76, 1994. View at Google Scholar · View at Scopus
  132. E. Hahnen, R. Forkert, C. Marke et al., “Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals,” Human Molecular Genetics, vol. 4, no. 10, pp. 1927–1933, 1995. View at Google Scholar · View at Scopus
  133. C. H. Wang, J. Xu, T. A. Carter et al., “Characterization of survival motor neuron (SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy,” Human Molecular Genetics, vol. 5, no. 3, pp. 359–365, 1996. View at Google Scholar · View at Scopus
  134. G. Stratigopoulos, P. Lanzano, L. Deng et al., “Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females,” Archives of Neurology, vol. 67, no. 10, pp. 1252–1256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Bowerman, C. L. Anderson, A. Beauvais, P. P. Boyl, W. Witke, and R. Kothary, “SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis,” Molecular and Cellular Neuroscience, vol. 42, no. 1, pp. 66–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Dimitriadi, J. N. Sleigh, A. Walker et al., “Conserved genes act as modifiers of invertebrate SMN loss of function defects,” PLoS Genetics, vol. 6, no. 10, Article ID e1001172, 2010. View at Google Scholar · View at Scopus
  137. A. Sharma, A. Lambrechts, L. thi Hao et al., “A role for complexes of survival of motor neurons (SMN) protein with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve cells,” Experimental Cell Research, vol. 309, no. 1, pp. 185–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. J. S. da Silva, M. Medina, C. Zuliani, A. di Nardo, W. Witke, and C. G. Dotti, “RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability,” Journal of Cell Biology, vol. 162, no. 7, pp. 1267–1279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Javaherian and H. T. Cline, “Coordinated motor neuron axon growth and neuromuscular synaptogenesis are promoted by CPG15 in vivo,” Neuron, vol. 45, no. 4, pp. 505–512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. E. Nedivi, G. Y. Wu, and H. T. Cline, “Promotion of dendritic growth by CPG15, an activity-induced signaling molecule,” Science, vol. 281, no. 5384, pp. 1863–1866, 1998. View at Publisher · View at Google Scholar · View at Scopus
  141. B. Akten, M. J. Kye, L. T. Hao et al., “Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 25, pp. 10337–10342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. C. Fallini, H. Zhang, Y. Su et al., “The Survival of Motor Neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons,” Journal of Neuroscience, vol. 31, no. 10, pp. 3914–3925, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Hubers, H. Valderrama-Carvajal, J. Laframboise, J. Timbers, G. Sanchez, and J. Côté, “HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects,” Human Molecular Genetics, vol. 20, no. 3, pp. 553–579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. E. E. Govek, S. E. Newey, C. J. Akerman, J. R. Cross, L. V. der Veken, and L. van Aelst, “The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis,” Nature Neuroscience, vol. 7, no. 4, pp. 364–372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  145. M. Bowerman, D. Shafey, and R. Kothary, “Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity,” Journal of Molecular Neuroscience, vol. 32, no. 2, pp. 120–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Bowerman, A. Beauvais, C. L. Anderson, and R. Kothary, “Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model,” Human Molecular Genetics, vol. 19, no. 8, pp. 1468–1478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. V. Caraballo-Miralles, A. Cardona-Rossinyol, A. Garcera et al., “SMN deficiency attenuates migration of U87MG astroglioma cells through the activation of RhoA,” Molecular and Cellular Neuroscience, vol. 49, no. 3, pp. 282–289, 2011. View at Publisher · View at Google Scholar
  148. A. Nölle, A. Zeug, J. van Bergeijk et al., “The spinal muscular atrophy disease protein SMN is linked to the rho-kinase pathway via profiling,” Human Molecular Genetics, vol. 20, no. 24, pp. 4865–4878, 2011. View at Google Scholar
  149. M. Bowerman, L. M. Murray, J. G. Boyer, C. L. Anderson, and R. Kothary, “Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy,” BMC Medicine, vol. 10, p. 24, 2012. View at Google Scholar
  150. L. Tönges, J. C. Koch, M. Bähr, and P. Lingor, “ROCKing regeneration: rho kinase inhibition as molecular target for neurorestoration,” Frontiers in Molecular Neuroscience, vol. 4, no. 39, pp. 1–11, 2011. View at Google Scholar
  151. X. Guo, K. Johe, P. Molnar, H. Davis, and J. Hickman, “Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to functional motoneurons,” Journal of Tissue Engineering and Regenerative Medicine, vol. 4, no. 3, pp. 181–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. S. Corti, F. Locatelli, D. Papadimitriou et al., “Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1,” Human Molecular Genetics, vol. 15, no. 2, pp. 167–187, 2006. View at Publisher · View at Google Scholar · View at Scopus
  153. L. Xu, D. K. Ryugo, T. Pongstaporn, K. Johe, and V. E. Koliatsos, “Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry,” Journal of Comparative Neurology, vol. 514, no. 4, pp. 297–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. L. Xu, P. Shen, T. Hazel, K. Johe, and V. E. Koliatsos, “Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats,” Neuroscience Letters, vol. 494, no. 3, pp. 222–226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Björklund and O. Lindvall, “Cell replacement therapies for central nervous system disorders,” Nature Neuroscience, vol. 3, no. 6, pp. 537–544, 2000. View at Publisher · View at Google Scholar · View at Scopus
  156. H. Wichterle, I. Lieberam, J. A. Porter, and T. M. Jessell, “Directed differentiation of embryonic stem cells into motor neurons,” Cell, vol. 110, no. 3, pp. 385–397, 2002. View at Publisher · View at Google Scholar · View at Scopus
  157. R. López-González, P. Kunckles, and I. Velasco, “Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells,” Cell Transplantation, vol. 18, no. 10-11, pp. 1171–1181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. N. Amariglio, A. Hirshberg, B. W. Scheithauer et al., “Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient,” PLoS Medicine, vol. 6, no. 2, Article ID e1000029, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  160. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, vol. 318, no. 5858, pp. 1917–1920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. I. H. Park, R. Zhao, J. A. West et al., “Reprogramming of human somatic cells to pluripotency with defined factors,” Nature, vol. 451, no. 7175, pp. 141–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. A. D. Ebert, J. Yu, F. F. Rose Jr. et al., “Induced pluripotent stem cells from a spinal muscular atrophy patient,” Nature, vol. 457, no. 7227, pp. 277–280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. T. Chang, W. Zheng, W. Tsark et al., “Phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient,” Stem Cell, vol. 29, no. 12, pp. 2090–2093, 2011. View at Google Scholar
  164. M. Wernig, J. P. Zhao, J. Pruszak et al., “Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5856–5861, 2008. View at Publisher · View at Google Scholar · View at Scopus
  165. G. Hargus, O. Cooper, M. Deleidi et al., “Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15921–15926, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. D. M. Deshpande, Y. S. Kim, T. Martinez et al., “Recovery from paralysis in adult rats using embryonic stem cells,” Annals of Neurology, vol. 60, no. 1, pp. 32–44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  167. J. M. Harper, C. Krishnan, J. S. Darman et al., “Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 18, pp. 7123–7128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  168. C. F. Rochette, N. Gilbert, and L. R. Simard, “SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens,” Human Genetics, vol. 108, no. 3, pp. 255–266, 2001. View at Publisher · View at Google Scholar · View at Scopus
  169. L. Cartegni and A. R. Krainer, “Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN,” Nature Genetics, vol. 30, no. 4, pp. 377–384, 2002. View at Publisher · View at Google Scholar · View at Scopus
  170. T. Kashima and J. L. Manley, “A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy,” Nature Genetics, vol. 34, no. 4, pp. 460–463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  171. S. Cho and G. Dreyfuss, “A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity,” Genes and Development, vol. 24, no. 5, pp. 438–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. B. Schrank, R. Götz, J. M. Gunnersen et al., “Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 18, pp. 9920–9925, 1997. View at Publisher · View at Google Scholar · View at Scopus